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Noncoding RNAs play important and diverse regulatory roles throughout the genome and make major
contributions to disease pathogenesis. The FMR1 gene is involved in three different syndromes: fragileeceived in revised form 16 July 2009





X syndrome (FXS), primary ovarian insufficiency (POI), and fragile X-associated tremor/ataxia syndrome
(FXTAS) in older patients. Noncoding RNAs have been implicated in the molecular pathogenesis of both
FXS and FXTAS. Here we will review our current knowledge on the role(s) of noncoding RNAs in FXS and
FXTAS, particularly the role of the microRNA pathway in FXS and the role of noncoding riboCGG (rCGG)
repeat in FXTAS.
© 2009 Elsevier Ireland Ltd. All rights reserved.XTAS
ecent genome-wide interrogations of transcribed RNA have
ielded compelling evidence for its pervasive and complex tran-
cription throughout most of the human genome. Nevertheless,
significant portion of this transcribed RNA appears to be non-
rotein-coding and is currently uncharacterized. In-depth analysis
f 1% of the human genome (∼30 Mb) performed by the Encyclo-
edia of DNA Elements (ENCODE) project revealed that 92.6% of
he interrogated bases could be detected as primary transcripts and
hat, among these, there were many novel non-protein-coding tran-
cripts [7]. Similarly, another study found that the majority (64%)
f polyadenylated (poly-A+) transcripts ≥200 nucleotides (nt) in
ength lay outside annotated protein-coding regions [35]. These
nd other genome-wide analyses have led to the identification of
ens of thousands of noncoding RNA transcripts expressed from the
uman genome, most of which have yet to be functionally char-
cterized. Along with the revelation that noncoding RNAs in the
uman genome are surprisingly abundant, there has been a surge
n molecular and genetic data showing diverse and important reg-
latory roles for noncoding RNA. It has been shown that both the
evelopment and proper function of the nervous system require thentricate spatiotemporal expression of a wide repertoire of regula-
ory RNAs. Misregulation of these regulatory RNAs could contribute
o the abnormalities in brain development that are associated with
eurodevelopmental disorders.
Fragile X syndrome (FXS) is the most common form of inher-
ted mental retardation, with an estimated prevalence of 1 in
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oi:10.1016/j.neulet.2009.07.0534000 males and 1 in 8000 females [58]. In addition to cognitive
deficits, the phenotype of fragile X syndrome includes mild facial
dysmorphology (prominent jaw, high forehead, and large ears),
macroorchidism in postpubescent males, and subtle connective
tissue abnormalities [58]. Many patients also manifest attention-
deficit hyperactivity disorder and autistic-like behavior. As the first
condition found to be caused by trinucleotide repeat expansion,
fragile X syndrome is typically the result of a massive CGG trinu-
cleotide repeat expansion within the 5′ untranslated region (UTR)
of the fragile X mental retardation 1 gene (FMR1), which results
in transcriptional silencing of FMR1 [19,39,47,48,57]. The majority
of affected individuals have expansions of over 200 CGG repeats,
referred to as the full mutation. Most people in the general pop-
ulation carry between 5 and 54 repeats, while those individuals
who carry CGG repeat expansions between 55 and 200 are referred
to as premutation carriers. Over the last several years, male and
to a lesser extent female premutation carriers are found to be at
increased risk of developing an age-dependent progressive inten-
tion tremor and ataxia syndrome, which is uncoupled from fragile
X syndrome [24] and known as fragile X-associated tremor/ataxia
syndrome (FXTAS) (Fig. 1). Besides a progressive action tremor
with ataxia, patients with FXTAS also show a progressive cogni-
tive decline that ranges from executive and memory deficits to
dementia [24]. In addition, female premutation carriers are also
found to have significantly higher rates of primary ovarian insuffi-
ciency (POI); however, the exact molecular basis of POI has yet to
be determined (Fig. 1).
Although both FXS and FXTAS involve CGG repeat expansions
in the FMR1 gene, the clinical presentations and molecular mecha-
nisms underlying each syndrome are distinct. Interestingly, recent
studies have implicated noncoding RNAs in the pathogenesis of
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Fig. 1. Mutations in the FMR1 gene can lead to three distinct disorders. The nor-
mal human FMR1 gene possesses a CGG trinucleotide repeat size of between 5
and 54 in the 5′ UTR. A large expansion of over 200 CGG repeats triggers the tran-
scriptional silencing of FMR1, which results in fragile X syndrome (FXS). For those












































rogressive neurodegenerative disorder, called fragile X-associated tremor/ataxia
yndrome (FXTAS), has been recognized among many male carriers in or beyond
heir fifth decade of life. Female carriers, on the other hand, may suffer from primary
varian insufficiency (POI).
oth disorders. Here we will review our current knowledge about
he involvement of noncoding RNAs in FXS and FXTAS, particularly
he role of the microRNA (miRNA) pathway in FXS and the role of
oncoding riboCGG (rCGG) repeat in FXTAS.
Identification of other mutations (e.g., deletions in patients with
he typical phenotype) has confirmed that FMR1 is the only gene
nvolved in the pathogenesis of fragile X syndrome and that the loss
f the FMR1 product, fragile X mental retardation protein (FMRP),
auses fragile X syndrome [14,44,60]. FMRP along with its auto-
omal paralogs, the fragile X-related proteins FXR1P and FXR2P,
onstitutes a small, well-conserved family of RNA-binding pro-
eins (fragile X-related gene family) that share over 60% amino
cid identity and contain two types of RNA-binding motifs: two
ibonucleoprotein K homology domains (KH domains) and a clus-
er of arginine and glycine residues (RGG box) [51,65]. Both the
H domains and RGG box of FMRP have been found to medi-
te FMRP-RNA interactions both in vitro and in vivo [2,16,17,41,43].
oth motifs contribute to the role of FMRP as a suppressor of tar-
et messenger RNA (mRNA) translation via binding of noncoding
NA structures, including G-quartets and “kissing complexes” (also
nown as loop-loop-pseudoknots), within the untranslated regions
f target mRNAs [2,12,13,16,41,43,50,53]. The ability of FMRP to bind
NA and suppress translation has definite clinical relevance, as evi-
enced by a severely affected individual with an I304N missense
utation in the KH2 domain of FMRP [17]. As an RNA-binding pro-
ein, FMRP is found to form a messenger ribonucleoprotein (mRNP)
omplex that associates with translating polyribosomes [16]. Fur-
hermore, FMRP is known to be involved in translational control
nd could suppress translation both in vitro and in vivo [41,43]. At
he cellular level, abnormal dendritic spines are found in the brains
f both human patients with fragile X syndrome and Fmr1 knock-
ut (KO) mice, implying that synaptic plasticity is affected in the
bsence of FMRP [11,46]. Based on these observations, it has been
roposed that FMRP is involved in synaptic plasticity via regulation
f mRNA transport and local protein synthesis of specific mRNAs
t synapses. Due to space limitations, we will focus here on the
otential role of the miRNA pathway in fragile X syndrome (for
n in-depth discussion of the molecular pathogenesis of fragile X
yndrome, please see the recent review by Bassell and Warren [6]).
MicroRNAs (miRNAs) are a new class of small noncoding RNAs
hat are ∼22 nucleotides (nt) in length and generated from endoge-ers 466 (2009) 103–108
nous double-strand transcripts [5]. Typically, miRNAs bind to the 3′
UTR of target mRNA, leading to translational repression or mRNA
degradation. The roles miRNAs play in diverse biological path-
ways have been reviewed extensively. Endogenous miRNAs were
found associated with FMRP, and FMRP interacts biochemically
and genetically with known components of the miRNA pathway
[8,28,61]. Experiments in Drosophila revealed specific biochemical
interactions between dFmrp and functional RNA-induced silenc-
ing complex (RISC) proteins, including dAGO1, dAGO2, and Dicer
[8,28,61]. dFmr1 displays strong genetic interaction with dAGO1,
and dAGO1 dominantly interacts with dFmr1 in both dFmr1 over-
expression and loss-of-function models [33]. Furthermore, dFmr1
also interacts genetically with AGO2, as exemplified by their abil-
ity to coregulate ppk1 mRNA levels [61]. Additional studies provide
further evidence for the involvement of FMRP in miRNA-containing
RISC and P body-like granules in Drosophila neurons [4]. Recombi-
nant human FMRP can also act as an acceptor for Dicer-derived
miRNAs, and importantly, endogenous miRNAs themselves are
associated with FMRP in both flies and mammals [8,28,33]. In the
adult mouse brain, Dicer and eIF2c2 (the mouse homolog of AGO1)
interact with FMRP at postsynaptic densities [45]. Recently, the
phosphorylation of FMRP was also shown to increase its association
with miRNA precursors [9,10]. Presumably, this interaction works
to regulate translation of target mRNAs in an activity-dependent
manner. Based on these findings, it has been proposed that the RISC
proteins, including Argonaute (Ago) and Dicer, could interact with
FMRP and use the loaded guide miRNA(s) to interact with target
sequences within the 3′ UTR of RNA bound to FMRP and suppress
its translation [31,33]. In this model, FMRP facilitates the interaction
between miRNAs and their target mRNA sequence, ensuring proper
targeting of guide miRNA-RISC within the 3′ UTRs and proper trans-
lational suppression.
The fact that FMRP is associated with Dicer, miRNAs, and specific
mRNA targets raises the question of whether FMRP is associated
with specific miRNAs and modulates their processing. To address
this question, the expression and processing of miRNAs were exam-
ined in Drosophila dFmr1 mutants; in the fly brain, dFmrp was
specifically associated with miR-124a, a nervous system-specific
miRNA [62]. dFmrp is required for the proper processing of pre-miR-
124a, whereas the loss of dFmr1 leads to a reduced level of mature
miR-124a and an increased level of pre-miR-124a. These results
suggest a modulatory role for dFmrp to maintain proper levels of
miRNAs during neuronal development [62]. In our own studies, we
have shown that dFmr1, the Drosophila ortholog of the FMR1 gene,
plays a role in the proper maintenance of germline stem cells in
Drosophila ovary, potentially through the miRNA pathway [63]. To
test this, we recently used an immunoprecipitation assay to reveal
that specific microRNAs (miRNAs), particularly the bantam miRNA
(bantam), are physically associated with dFmrp in ovary [64]. We
found that, like dFmr1, bantam is not only required for repressing
primordial germ cell differentiation, it also functions as an extrin-
sic factor for germline stem cell maintenance [64]. Furthermore,
we showed that bantam genetically interacts with dFmr1 to reg-
ulate the fate of germline stem cells [64]. Collectively, our results
support the notion that the FMRP-mediated translational pathway
functions through specific miRNAs to control stem cell regulation;
however, we saw no effect of dFmrp on the biogenesis of the ban-
tam miRNA. Whether FMRP is associated with specific miRNAs in
mammalian cells remains to be determined.
All the current findings support the idea that FMRP could
regulate the translation of its mRNA through miRNA interaction.
However, the exact mechanism of its action together with the
RISC and miRNAs is not yet clear. Thus the relevance of these
observations to FMRP-mediated translational regulation and the
possible involvement of miRNAs in mental retardation more gen-
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Fragile X-associated tremor/ataxia syndrome (FXTAS) has been
ecognized in older males of FXS families and is uncoupled from
he neurodevelopmental disorder, FXS [23]. Although both dis-
rders involve repeat expansions in the FMR1 gene, the clinical
resentation and molecular mechanisms underlying each are com-
letely distinct. The most common clinical feature of FXTAS is a
rogressive action tremor with ataxia. More advanced or severe
ases may show a worsening cognitive decline that ranges from
xecutive and memory deficits to dementia [22]. Patients may also
resent with common psychiatric symptoms, such as increased
nxiety, mood liability, and depression [3,27]. Nearly all case studies
rom autopsies on the brains of symptomatic premutation carri-
rs demonstrate degeneration in the cerebellum, which includes
urkinje neuronal cell loss, Bergman gliosis, spongiosis of the deep
erebellar white matter, and swollen axons [20,21]. The major neu-
opathological hallmark and postmortem criterion for definitive
XTAS are eosinophilic, ubiquitin-positive intranuclear inclusions
ocated in broad distribution throughout the brain in neurons,
strocytes, and in the spinal column [20]. The inclusions are both
au and -synuclein negative, which indicates that FXTAS is not a
auopathy or synucleinopathy. Notably, the FXTAS inclusions share
he same ubiquitin-positive hallmark as several other inclusion dis-
ases, such as polyglutamine disorders, yet the inclusions do not
tain with antibodies that recognize polyglutamine, which suggests
defect in the proteasomal degradation pathway [21,24,54]. Fur-
hermore, unlike the polyglutamine disorders, there is no known
tructurally abnormal protein associated with FXTAS.
One logical explanation for the variability in the FXTAS clini-
al phenotype might be variability in the size of the premutation
lleles of individual patients. Interestingly, all these patients are
arriers of a premutation-size CGG repeat (55–200 triplets) in the
′ UTR of the FMR1 gene. The repeat is expressed in the mature
MR1 mRNA in premutation carriers, as well as in individuals with
ormal CGG repeat lengths. A study of families with known FXS
robands into the penetrance of tremor and ataxia among premu-
ation carriers revealed that more than a third of carriers 50 years
r older show symptoms of FXTAS, and that the penetrance of this
isorder exceeds 50% for men over 70 years of age [29]. The preva-
ence of premutation alleles is approximately 1 in 800 for males
nd 1 in 250 for females in the general population; however, it is
stimated that 1 in 3000 men over 50 in the general population will
ig. 2. Genotype–phenotype correlation at the FMR1 locus. In fragile X syndrome, large e
ene cause hypermethylation of the FMR1 promoter, which leads to the transcriptional sil
RNA is elevated some two to eight times above normal levels in premutation carriers (55
elow normal levels. The observation of increased FMR1 mRNA levels in premutation carrers 466 (2009) 103–108 105
show symptoms of FXTAS [15]. These estimates do not consider a
size bias, which takes into account the correlation between the age
of onset of symptoms and the size of the repeat. Recent studies
have correlated the age of onset of clinical FXTAS symptoms with
the length of expanded repeats and shown that larger CGG repeats
represent an increased risk factor for the development of FXTAS
[30,42]. Moreover, the degree of brain atrophy and severity of the
tremor and ataxia are associated with the CGG repeat length [42].
Some female carriers also develop clinical features of FXTAS, but at
a much lower frequency than males, which may be due to partial
protection conferred by random X-inactivation of the premutation
allele [25,29,66].
At the molecular level, the premutation is different from either
the normal or full mutation alleles. Besides the obvious difference
of the CGG repeat length itself, there are a number of other dis-
tinctions. In cells from premutation carriers over a wide range of
repeat lengths, the level of FMR1 mRNA is elevated some two to
eight times above normal levels, while the stability of FMR1 mRNA is
unchanged (Fig. 2). Indeed, even in the high-end normal range (∼55
repeats), the FMR1 message level was near double that found in nor-
mal alleles (∼30 repeats) [36,55]. In addition, some hypomethylated
full mutation alleles produce substantial amounts of FMR1 message
(∼4.5-fold normal) [55]. Although the precise mechanism for this
overexpression is unknown, it is likely that the increasing length
of the CGG repeat near the FMR1 promoter proportionally opens
the chromatin, allowing more ready access to transcription factors.
Despite this elevation in FMR1 levels, the amount of FMR1 protein is
modestly reduced in the premutation range (∼80% of normal) and
may be largely absent in cells expressing FMR1 message with very
long repeats (>300 repeats) [18,36]. This paradoxical reduction of
translation despite elevated mRNA levels can be explained by the
fact that long CGG repeats in the FMR1 mRNA impede 40S ribo-
somal subunit migration from the 5′ cap to the initiating codon.
It is unlikely that overexpression of FMR1 mRNA is a response to
the reduction of FMRP levels, as I304N mutant cells with 30 CGG
repeats, which produce nonfunctional protein, do not show an ele-
vated FMR1 mRNA [16,36].An RNA gain-of-function mechanism has been suggested for
FXTAS based on the observation of increased levels of CGG-
containing FMR1 mRNA, along with either no detectable change
in FMRP or slightly reduced FMRP levels in premutation carriers
xpansions of the CGG trinucleotide repeat (>200 repeats) in the 5′ UTR of the FMR1
encing of FMR1 and the loss of the FMR1 product, FMRP. However, the level of FMR1
–200 CGG repeats), whereas the amount of FMRP appeared to remain at or slightly
iers supports the idea that FXTAS is an RNA-mediated neurodegenerative disorder.

































































Fig. 3. RNA-binding proteins (RBPs) are involved in FXTAS pathogenesis. Three RNA-
binding proteins, Pur , hnRNP A2/B1, and CUGBP1, were found to bind rCGG repeats
either directly (Pur  and hnRNP A2/B1) or indirectly (CUGBP1, through the inter-
action with hnRNP A2/B1). HnRNP A2/B1 forms a complex with CUGBP1 to bind to
rCGG repeats, which is independent of Pur . Overexpression of these proteins can
suppress neuronal cell death caused by fragile X premutation rCGG repeats, sup-06 H. Tan et al. / Neuroscien
21,29,34,55,59]. The absence of FXS, which results from the loss-
f-function of the FMR1 gene product, in patients with FXTAS, along
ith the absence of FXTAS symptoms in older individuals with
XS also suggests a role for the expanded rCGG repeat in FXTAS
athology. This type of RNA gain-of-function mechanism may also
ccount for some triplet repeat-related ataxias, such as spinocere-
ellar ataxia type 8 (SCA8), SCA10, and SCA12, and in myotonic
ystrophy (DM) [49]. The untranslated repeat expansion in DM has
n fact given us major insight into the underlying molecular mecha-
isms of FXTAS. DM1 is caused by a CTG repeat expansion in a region
f the 3′ UTR of the DMPK gene that is transcribed into RNA but not
ranslated into protein. The mutant transcripts sequester MBNL and
ther proteins, which form ribonuclear foci or inclusions. Indeed,
sing in situ hybridization, Tassone et al. demonstrated the pres-
nce of expanded FMR1 RNA transcripts in the FXTAS inclusions of
70-year-old male who died with FXTAS [56].
Beyond the observation of increased levels of CGG-containing
MR1 mRNA in fragile X premutation carriers, several other lines of
vidence further support an RNA-mediated gain-of-function toxi-
ity model for FXTAS. First, in a “knock-in” mouse model, in which
he endogenous CGG repeats (five CGG repeats in the wild-type
ouse Fmr1 gene) were replaced with a ∼100-CGG repeat frag-
ent, intranuclear inclusions were found to be present throughout
he brain, with the exception of cerebellar Purkinje cells [59]. There
as an increase in both the number and size of the inclusions over
he life course, which correlates with the progressive character of
he phenotype observed in humans [20]. Second, neuropathologi-
al studies in humans have revealed a highly significant association
etween length of the CGG tract and frequency of intranuclear
nclusions in both neurons and astrocytes, indicating that the CGG
epeat length is a powerful predictor of neurological involvement
linically (age of death) as well as neuropathologically (number of
nclusions) [20]. Third, intranuclear inclusions can be formed in
oth primary neural progenitor cells and established neural cell
ines, as was revealed using a reporter construct with an FMR1 5′
TR harboring expanded (premutation) CGG repeats [1]. Fourth,
e described a model of FXTAS using Drosophila expressing the
MR1 untranslated CGG repeats 5′ to the EGFP coding sequence
nd demonstrated that premutation-length rCGG repeats are both
oxic and sufficient to cause neurodegeneration [34]. And finally, it
as been found recently that rCGG expressed in Purkinje neurons
utside the context of Fmr1 mRNA can result in neuronal pathol-
gy in a mammalian system [26]. These observations led us and
thers to propose that transcription of the CGG90 repeats leads to
n RNA-mediated neurodegenerative disease. We further posited
mechanism by which rCGG repeat-binding proteins (RBPs) may
ecome functionally limited by their sequestration to lengthy rCGG
epeats, mechanistically similar to the pathophysiology of DM1.
To test this model using both biochemical and genetic
pproaches, we and others have identified three proteins, Pur ,
nRNP A2/B1 (two protein isoforms from one gene), and CUGBP1,
hich bind rCGG repeats either directly (Pur  and hnRNP A2/B1)
r indirectly (CUGBP1, through the interaction with hnRNP A2/B1)
32,52]. Thus, there are protein complexes that physically inter-
ct with rCGG repeats, and all of these are RNA-binding proteins
hat have been shown to function in transcription, mRNA traffick-
ng, splicing, and translation. Interestingly, Pur  knock-out mice
ppeared normal at birth, but developed severe tremor and sponta-
eous seizures at two weeks of age due to drastically lower numbers
f neurons in regions of the hippocampus and cerebellum [37]. The
ypothesis is that overproduced rCGG repeats in FXTAS sequester
hese proteins from their normal cellular functions, contributing
ignificantly to the pathology of this disorder. This idea is given
trong support by the fact that overexpressing either Pur  or hnRNP
2/B1 alleviated neurodegeneration in a fly model of FXTAS [32,52].
he next important step will now be to further identify the RNAsporting the model that sequestration of these proteins by the overproduced rCGG
repeats in FXTAS prevents them from carrying out their normal functions, leading
to abnormal RNA metabolism and neurodegeneration.
regulated by these proteins that are altered by the expression of
rCGG repeats and contribute to the pathogenesis of FXTAS (Fig. 3).
Interestingly an antisense transcript, ASFMR1, has recently been
identified to overlap the CGG repeat region of the FMR1 gene
[38,40]. Similar to FMR1, the ASFMR1 transcript is silenced in
full mutation individuals and up-regulated in premutation carri-
ers. However, whether ASFMR1 contributes to the pathogenesis of
either FXTAS or FXS remains to be determined.
It is remarkable that the same type of mutation in the FMR1 gene
is involved in three distinct disorders that affect patients in an age-
dependent manner (Fig. 1). Interestingly, two of these syndromes,
FXS and FXTAS, are known to be caused, at least in part, by altered
noncoding RNA-mediated gene regulation. Understanding the role
of noncoding RNAs in these diseases will not only help unravel the
molecular pathogenesis of fragile X-related disorders, but will also
tell us much about the role of noncoding RNAs in human diseases
in general.
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